Azenta (AZTA) 10-Q 9 Feb 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	3 Months Ended
	Dec. 31, 2021	Feb. 04, 2022
Cover [Abstract]
Entity Central Index Key	0000933974
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	000-25434
Entity Registrant Name	AZENTA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	15 Elizabeth Drive
Entity Address, City or Town	Chelmsford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01824
City Area Code	978
Local Phone Number	262-2400
Title of 12(b) Security	Common Stock, $0.01 par value
Entity Listing, Par Value Per Share	$ 0.01
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,915,975
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Current assets
Cash and cash equivalents	$ 215,168	$ 227,427
Marketable securities	51	81
Accounts receivable, net	126,001	119,877
Inventories	70,143	60,398
Prepaid expenses and other current assets	60,833	58,198
Current assets held for sale	324,533	311,385
Total current assets	796,729	777,366
Property, plant and equipment, net	147,261	130,719
Long-term marketable securities	3,724	3,598
Long-term deferred tax assets	13,845	10,043
Goodwill	468,585	469,356
Intangible assets, net	178,589	186,534
Other assets	60,042	58,068
Non-current assets held for sale	186,162	183,828
Total assets	1,854,937	1,819,512
Current liabilities
Accounts payable	46,869	42,360
Deferred revenue	28,483	25,724
Accrued warranty and retrofit costs	2,342	2,330
Accrued compensation and benefits	24,872	33,183
Accrued restructuring costs	142	304
Accrued income taxes payable	14,037	8,711
Accrued expenses and other current liabilities	104,306	103,537
Current liabilities held for sale	120,749	128,939
Total current liabilities	341,800	345,088
Long-term debt	49,702	49,677
Long-term tax reserves	1,995	1,973
Long-term deferred tax liabilities	13,141	13,030
Long-term pension liabilities	726	705
Long-term operating lease liabilities	43,802	45,088
Other long-term liabilities	4,372	6,173
Non-current liabilities held for sale	31,976	32,444
Total liabilities	487,514	494,178
Commitments and contingencies (Note 21)
Stockholders' Equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value - 125,000,000 shares authorized, 87,808,922 shares issued and 74,347,053 shares outstanding at September 30, 2021, 87,293,710 shares issued and 73,831,841 shares outstanding at September 30, 2020	884	878
Additional paid-in capital	1,977,571	1,976,112
Accumulated other comprehensive income	24,149	19,351
Treasury stock, at cost - 13,461,869 shares	(200,956)	(200,956)
Accumulated deficit	(434,225)	(470,051)
Total stockholders' equity	1,367,423	1,325,334
Total liabilities and stockholders' equity	$ 1,854,937	$ 1,819,512

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Sep. 30, 2021
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	88,375,410	87,808,922
Common stock, shares outstanding	74,913,541	74,347,053
Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]
Treasury stock, shares	13,461,869	13,461,869

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue
Total revenue	$ 139,652	$ 118,142
Cost of revenue
Total cost of revenue	72,608	60,807
Gross profit	67,044	57,335
Operating expenses
Research and development	6,485	5,088
Selling, general and administrative	60,711	51,930
Restructuring charges	173	(40)
Total operating expenses	67,369	56,979
Operating (loss) income	(325)	356
Interest income	35	76
Interest expense	(455)	(557)
Other income (expenses), net	(1,077)	1,281
(Loss) income before income taxes	(1,822)	1,156
Income tax benefit	(4,680)	(1,550)
Income from continuing operations	2,858	2,706
Income from discontinued operations, net of tax	40,462	23,322
Net income	$ 43,320	$ 26,028
Basic net income per share:
Income from continuing operations (in dollars per share)	$ 0.04	$ 0.04
Income from discontinued operations, net of tax (in dollars per share)	0.54	0.32
Basic net income per share (in dollars per share)	0.58	0.35
Diluted net income per share:
Income from continuing operations (in dollars per share)	0.04	0.04
Income from discontinued operations, net of tax (in dollars per share)	0.54	0.31
Diluted net income per share (in dollars per share)	$ 0.58	$ 0.35
Weighted average shares used in computing net income per share:
Basic (in shares)	74,630	74,021
Diluted (in shares)	74,866	74,283
Products
Revenue
Total revenue	$ 45,869	$ 41,462
Cost of revenue
Total cost of revenue	24,523	22,793
Services
Revenue
Total revenue	93,783	76,680
Cost of revenue
Total cost of revenue	$ 48,085	$ 38,014

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 43,320	$ 26,028
Other comprehensive income, net of tax:
Foreign currency translation adjustments	4,801	13,264
Actuarial gains (losses), net of tax effects of $0 and $5 during the three months ended December 31, 2021 and 2020	(3)	(38)
Total other comprehensive income, net of tax	4,798	13,226
Comprehensive income	$ 48,118	$ 39,254

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Actuarial gains (losses)	$ 0	$ 5

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income	$ 43,320	$ 26,028
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	12,883	15,746
Stock-based compensation	7,891	6,710
Amortization of premium on marketable securities and deferred financing costs	56	56
Deferred income taxes	(3,084)	(4,960)
(Gain) loss on disposals of assets	(95)	1
Adjustment to the gain on divestiture, net of tax		948
Changes in operating assets and liabilities, net of acquisitions and divestiture:
Accounts receivable	1,121	(4,504)
Inventories	(32,150)	(6,307)
Prepaid expenses and other assets	(19,647)	28,945
Accounts payable	(2,219)	5,727
Deferred revenue	4,056	3,186
Accrued warranty and retrofit costs	(103)	(185)
Accrued compensation and tax withholdings	(5,371)	(12,307)
Accrued restructuring costs	(154)	(75)
Accrued expenses and other liabilities	9,114	(15,279)
Net cash provided by operating activities	15,618	43,730
Cash flows from investing activities
Purchases of property, plant and equipment	(18,409)	(15,227)
Purchases of marketable securities	(46)	(4)
Sales of marketable securities	30
Acquisitions, net of cash acquired		(15,061)
Net cash used in investing activities	(18,425)	(30,292)
Cash flows from financing activities
Principal repayments of finance lease obligations	(186)	(319)
Principal payments on debt		(414)
Common stock dividends paid	(7,494)	(7,424)
Net cash used in financing activities	(7,680)	(8,157)
Effects of exchange rate changes on cash and cash equivalents	(1,804)	11,250
Net (decrease) increase in cash, cash equivalents and restricted cash	(12,291)	16,531
Cash, cash equivalents and restricted cash, beginning of period	285,333	302,526
Cash, cash equivalents and restricted cash, end of period	273,042	319,057
Supplemental disclosures:
Cash paid for interest	333	370
Cash paid for income taxes, net	$ 10,911	$ 3,697

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents of continuing operations	$ 215,168	$ 263,517
Cash and cash equivalents included in assets held for sale	45,000	45,000
Short-term restricted cash included in prepaid expenses and other current assets	3,568	3,571
Long-term restricted cash included in other assets	9,306	6,969
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 273,042	$ 319,057
Restricted Cash, Current, Statement of Financial Position	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Restricted Cash, Noncurrent, Statement of Financial Position	Other assets	Other assets

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Inc. Stockholders' Equity	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Total
Beginning Balance at Sep. 30, 2020	$ 1,213,614	$ 873	$ 1,942,850	$ 21,919	$ (551,072)	$ (200,956)	$ 1,213,614
Beginning Balance (in shares) at Sep. 30, 2020		87,293,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net		$ 4	(4)
Shares issued under restricted stock and purchase plans, net (in shares)		378,422
Stock-based compensation	6,710		6,710				6,710
Common stock dividends declared	(7,424)				(7,424)		(7,424)
Net income	26,028				26,028		26,028
Foreign currency translation adjustments	13,264			13,264			13,264
Actuarial loss, net of tax effects	(38)			(38)			(38)
Ending Balance at Dec. 31, 2020	1,252,154	$ 877	1,949,556	35,145	(532,468)	(200,956)	1,252,154
Ending Balance (in shares) at Dec. 31, 2020		87,672,132
Beginning Balance at Sep. 30, 2021	1,325,334	$ 878	1,976,112	19,351	(470,051)	(200,956)	$ 1,325,334
Beginning Balance (in shares) at Sep. 30, 2021		87,808,922					74,347,053
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net		$ 6	(6)
Shares issued under restricted stock and purchase plans, net (in shares)		566,488
Stock-based compensation	1,465		1,465				$ 1,465
Common stock dividends declared	(7,494)				(7,494)		(7,494)
Net income	43,320				43,320		43,320
Foreign currency translation adjustments	4,801			4,801			4,801
Actuarial loss, net of tax effects	(3)			(3)			(3)
Ending Balance at Dec. 31, 2021	$ 1,367,423	$ 884	$ 1,977,571	$ 24,149	$ (434,225)	$ (200,956)	$ 1,367,423
Ending Balance (in shares) at Dec. 31, 2021		88,375,410					74,913,541

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Dividend declared per share (in dollars per share)	$ 0.10	$ 0.10
Actuarial losses, tax	$ 0	$ 5

Nature of Operation

Nature of Operation	3 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operation	1. Nature of Operation Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of life science sample exploration and management solutions for the life sciences market. The Company supports its customers from research to clinical development with its sample management, automated storage, and genomic services expertise to help bring impactful therapies to market faster. Discontinued Operations In the fourth quarter of fiscal year 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (“THL”). The Company determined that the semiconductor automation business met the “held for sale” criteria and the “discontinued operations” criteria in accordance with Financial Accounting Standard Boards (“FASB”) Accounting Standards Codification (“ASC”) 205, Presentation of Financial Statements On February 1, 2022, subsequent to the close of our first fiscal quarter of 2022, the Company completed the sale of the semiconductor automation business for $3.0 billion in cash, subject to working capital and other customary adjustments. The Company expects net cash proceeds from the sale to be approximately $2.4 billion, after adjustments and deducting taxes and other items. Risks and Uncertainties The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its of new technological innovations, risk of disruption in its supply chain, the implementation of tariffs and export controls, dependence on key personnel, protection of proprietary technology, and compliance with domestic and foreign regulatory authorities and agencies. During the COVID-19 pandemic, the Company’s facilities have remained operational with only required personnel on site, and the balance of employees working from home. The Company’s business falls within the classification of an “Essential Critical Infrastructure Sector” as defined by the U.S. Department of Homeland Security and the Company has continued operations during the COVID-19 pandemic. The Company has followed government guidance in each region and has implemented the U.S. Centers for Disease Control and Prevention social distancing guidelines and other best practices to protect the health and safety of the Company’s employees. The COVID-19 pandemic has not had a substantial negative impact on the Company’s financial results and a portion of this impact has been mitigated by the Company’s realignment of resources to satisfy incremental orders related to virus research and vaccine development and commercialization. Future impacts on the Company’s financial results are not fully determinable, as the full impact of the pandemic on the economy and markets which the Company serves is as yet unknown, but will be dependent, in part, on future variants of the virus and vaccine effectiveness against these variants and new or prolonged government responses to the pandemic. The Company’s financial results will also depend on variables including reduced demand from its customers, the degree that the supply chain may be constrained which could impact its delivery of product and the potential impact to its operations if there is a significant outbreak among the Company’s employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats .

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company applies the equity method of accounting to investments that provide it with the ability to exercise significant influence over the entities in which it lacks controlling financial interest and is not a primary beneficiary. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission for the fiscal year ended September 30, 2021 (the “2021 Annual Report on Form 10-K”). The accompanying Consolidated Balance Sheet as of September 30, 2021 was derived from the audited annual consolidated financial statements as of the period then ended. Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue recognized in accordance with the percentage of completion method, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and record changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, sales, expenses, reserves and allowances, manufacturing and employee-related amounts, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. ​ Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses), net” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $1.9 million and net foreign currency transaction and remeasurement gains were $0.8 million during the three months ended December 31, 2021 and 2020, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of all of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income” in the Company’s Consolidated Balance Sheets and presented as a component of comprehensive income in the Company’s Consolidated Statements of Comprehensive Income. Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than U.S. dollars. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses), net” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ December 31, ​ ​ 2021 2020 Realized losses on derivatives not designated as hedging instruments ​ $ (70) ​ $ (1,162) ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts. Fair Value Measurements The Company measures certain financial assets and liabilities, including cash equivalents and available for sale securities, at fair value. FASB ASC 820, Fair Value Measurement and Disclosures Level 1 Inputs: Level 2 Inputs: Level 3 Inputs: As of December 31, 2021, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs. Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets. Recently Issued Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in the first quarter of fiscal 2023. The Company is evaluating the effect of adopting this new accounting guidance. ​ In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01 , Reference Rate Reform (Topic 848): Scope . The amendments provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the amendments are only available until December 31, 2022, when the reference rate replacement activity is expected to be completed. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures. ​ Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . There is no accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU will not affect the Company's consolidated financial statements. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s disclosure to the consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2021 Annual Report on Form 10-K. ​ ​ ​ ​

Discontinued Operations

Discontinued Operations	3 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations Planned Disposition of Semiconductor Automation Business On September 20, 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to THL. On February 1, 2022, subsequent to the close of our first fiscal quarter of 2022, the Company completed the sale of the semiconductor automation business for $3.0 billion in cash, subject to working capital and other customary adjustments. The Company expects net cash proceeds from the sale to be approximately $2.4 billion, after adjustments, taxes and other items. The semiconductor automation business is comprised of the Semiconductor Solution Group segment. Following the completion of the sale, the Company no longer serves the semiconductor market. In connection with the closing of the sale, the Company and THL entered into a transition services agreement, to which both the Company and THL will provide each other with certain transition services related to finance and accounting, information technology, human resources, compliance, facilities, legal and research and development support, for time periods ranging from three . In addition, the Company entered into two separate lease agreements for leases back to the Company for portions of the facilities that have served as its corporate headquarters in Chelmsford, Massachusetts, and were sold to THL as part of the sale agreement. Each lease provides for a term of 24 months , which may be terminated earlier by the Company upon 90 days ’ notice to THL. During the fourth quarter of fiscal 2021, the Company determined that the semiconductor automation business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results are reflected in the Company’s financial statements as a discontinued operation, and assets and liabilities were classified as assets and liabilities held for sale. The following table presents the financial results of discontinued operations with respect to the semiconductor automation business (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ 2021 ​ 2020 Revenue ​ ​ ​ ​ ​ Products ​ $ 188,240 ​ $ 118,154 Services ​ ​ 15,430 ​ ​ 13,207 Total revenue ​ ​ 203,670 ​ ​ 131,361 Cost of revenue ​ ​ ​ ​ ​ ​ Products ​ ​ 107,597 ​ ​ 68,777 Services ​ ​ 8,309 ​ ​ 6,791 Total cost of revenue ​ ​ 115,906 ​ ​ 75,568 Gross profit ​ ​ 87,764 ​ ​ 55,793 Operating expenses ​ ​ ​ ​ ​ ​ Research and development ​ ​ 13,740 ​ ​ 10,994 Selling, general and administrative ​ ​ 22,676 ​ ​ 14,099 Restructuring charges ​ ​ - ​ ​ 127 Total operating expenses ​ ​ 36,416 ​ ​ 25,220 Operating income ​ ​ 51,348 ​ ​ 30,573 Other income (loss), net ​ ​ (46) ​ ​ (1,239) Income before income taxes ​ ​ 51,302 ​ ​ 29,334 Income tax provision ​ ​ 10,840 ​ ​ 6,012 Net income from discontinued operations ​ $ 40,462 ​ $ 23,322 ​ ​ On July 1, 2019, the Company sold its semiconductor cryogenics business. During the first quarter of fiscal year ended 2021, the Company recorded a $1.3 million negative working capital adjustment to the gain on divestiture that was previously recorded in the fourth fiscal quarter of 2019. This adjustment is shown within Other income (loss), net within the income statement for the semiconductor automation business. The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the semiconductor automation business that are included in the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ ​ 2021 ​ ​ 2020 Depreciation and amortization ​ $ - ​ $ 2,019 Capital expenditures ​ $ 2,283 ​ $ 1,827 Stock-based compensation ​ ​ 4,923 ​ ​ 1,875 ​ ​ The carrying value of the assets and liabilities of the discontinued operations with respect to the semiconductor automation business on the Consolidated Balance Sheets as of December 31, 2021 and September 30, 2021 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ September 30, 2021 Assets ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 45,000 ​ $ 45,000 Accounts receivable, net ​ ​ 133,578 ​ ​ 142,256 Inventories ​ ​ 132,010 ​ ​ 110,735 Other current assets ​ ​ 13,945 ​ ​ 13,394 Total current assets of discontinued operation ​ $ 324,533 ​ $ 311,385 ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, net ​ $ 34,457 ​ $ 32,058 Long-term deferred tax assets ​ ​ 2,518 ​ ​ 3,167 Goodwill ​ ​ 81,514 ​ ​ 81,477 Intangibles, net ​ ​ 44,576 ​ ​ 44,468 Other assets ​ ​ 23,097 ​ ​ 22,658 Total long-term assets of discontinued operation ​ $ 186,162 ​ $ 183,828 ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 65,285 ​ $ 68,074 Deferred revenue ​ ​ 8,160 ​ ​ 7,141 Accrued warranty and retrofit costs ​ ​ 5,912 ​ ​ 6,081 Accrued compensation and benefits ​ ​ 20,963 ​ ​ 18,144 Accrued Income Taxes ​ ​ 6,184 ​ ​ 11,702 Accrued expenses and other current liabilities ​ ​ 14,454 ​ ​ 18,014 Total current liabilities of discontinued operation ​ $ 120,958 ​ $ 129,156 ​ ​ ​ ​ ​ ​ ​ Long-term tax reserves ​ ​ 2,373 ​ ​ 2,356 Long-term deferred tax liabilities ​ ​ 6,716 ​ ​ 6,548 Long-term pension liabilities ​ ​ 5,547 ​ ​ 5,490 Long-term operating lease liabilities ​ ​ 15,837 ​ ​ 15,425 Other long-term liabilities ​ ​ 1,503 ​ ​ 2,625 Total long-term liabilities of discontinued operation ​ $ 31,976 ​ $ 32,444 ​ ​ Acquisition within the Semiconductor Automation Business On April 29, 2021, the Company acquired Precise Automation Inc., a leading developer of collaborative robots and automation subsystems headquartered in Fremont, California. The total cash purchase price for the acquisition was approximately $69.8 million. Precise provides the semiconductor automation business with a product offering and technology portfolio to take advantage of the opportunities in the collaborative robot market. The allocation of the consideration included $38.7 million of technology, $2.5 million of customer relationships, $33.1 million of goodwill, $6.2 million of deferred tax liabilities, and several other assets and liabilities. The purchase price allocation was based on a preliminary valuation which is subject to further adjustments within the measurement period when additional information becomes available. The Company applied variations of the income approach to estimate the fair values of the intangible assets acquired. The completed technology was valued using excess earnings method and the customer relationships was valued using distributor margin method, both of which have a useful life of 11 years. The intangible assets acquired are amortized over the total weighted average period of 11 years using methods that approximate the pattern in which the economic benefits are expected to be realized. The Company has included the financial results of the acquired operations within income from discontinued operations on its Consolidated Statements of Operations. The goodwill and intangible assets are not The Company did not present a pro forma information summary for its consolidated results of operations because such results were immaterial.

Marketable Securities

Marketable Securities	3 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the accompanying unaudited Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. Unrealized gains and losses are excluded from earnings and reported as a separate component of “accumulated other comprehensive income, net of tax” in the accompanying unaudited Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of "Other income (expenses), net" in the accompanying unaudited Consolidated Statements of Operations. There were insignificant sales of marketable securities for the three months ended December 31, 2021 and 2020. The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value December 31, 2021: ​ ​ ​ ​ Bank certificates of deposits ​ $ 25 ​ $ — ​ $ — ​ $ 25 Corporate securities ​ ​ 3,703 ​ ​ — ​ ​ — ​ ​ 3,703 Municipal securities ​ 46 ​ ​ — ​ ​ — ​ 46 ​ ​ $ 3,774 ​ $ — ​ $ — ​ $ 3,774 September 30, 2021: ​ ​ ​ ​ ​ Bank certificates of deposits ​ $ 30 ​ $ — ​ $ — ​ $ 30 Corporate securities ​ ​ 3,624 ​ ​ — ​ ​ — ​ ​ 3,624 Other debt securities ​ 25 ​ ​ — ​ ​ — ​ 25 ​ ​ $ 3,679 ​ $ — ​ $ — ​ $ 3,679 ​ ​ The fair values of the marketable securities by contractual maturities at December 31, 2021 are presented below (in thousands): ​ ​ ​ ​ ​ Fair Value Due in one year or less ​ $ 46 Due after one year through five years ​ 51 Due after five years through ten years ​ ​ — Due after ten years ​ 3,677 Total marketable securities ​ $ 3,774 ​ Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. There was an insignificant amount of securities in an unrealized loss position as of December 31, 2021. There were no securities in an unrealized loss position as of September 30, 2021.

Acquisitions

Acquisitions	3 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisitions	5. Acquisitions The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The finalization of the assignment of fair values will be completed within one year after the respective acquisition date. The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions completed because such results were immaterial. ​ Abeyatech LLC ​ On April 2, 2021, the Company acquired Abeyatech LLC. The Company has included the financial results of the acquired operations within the Life Sciences Products segment. The purchase price includes $9.9 million cash payment and $9.4 million in contingent consideration based on the acquired business’ performance for the twelve-month period ending December 31, 2021, subject to customary working capital adjustments and other adjustments. The acquisition enhances the breadth and depth of the Company’s offerings and expands its expertise in the Life Sciences Products segment. The allocation of the consideration included $11.9 million of technology, $4.4 million of goodwill, and several other assets and liabilities for $3.0 million. The weighted useful life of all the intangible assets acquired is 12 years. The purchase price allocation was based on a preliminary valuation which is subject to further adjustments within the measurement period when additional information becomes available. The goodwill and intangibles are tax deductible ​ Trans-Hit Biomarkers, Inc. ​ On December 3, 2020, the Company acquired Trans-Hit Biomarkers Inc. (“THB”), a worldwide biospecimen procurement service provider based in Montreal Canada. THB has an extensive collection capability for biospecimens and clinical samples through a worldwide partner network of clinical sites and biobanks. The total cash purchase price of the acquisition was approximately $15.1 million, net of cash acquired. The acquisition enhances the breadth and depth of the Company’s offerings and expands its expertise in the Life Sciences Services segment. The allocation of the consideration included $7.8 million of customer relationships, $9.3 million of goodwill, $2.4 million of deferred tax liabilities, and several other assets and liabilities. The weighted useful life of all intangibles acquired is 11 years . The Company has included the financial results of the acquired operations in the Life Sciences Services segment. The goodwill and intangibles are not tax deductible.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill represents the excess of net book value over the estimated fair value of net tangible and identifiable intangible assets of a reporting unit. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. If events occur or circumstances change that would more likely than not reduce fair values of the reporting units below their carrying values, goodwill will be evaluated for impairment between annual tests. No triggering events indicating goodwill impairment occurred during the three months ended December 31, 2021. Please refer to Note 8, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2021 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2021. The changes in the Company’s goodwill by reportable segment since September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2021 ​ 110,138 ​ 359,218 ​ 469,356 Currency translation adjustments ​ (737) ​ (34) ​ (771) Balance, at December 31, 2021 ​ $ 109,401 ​ $ 359,184 ​ $ 468,585 ​ ​ During the three months ended December 31, 2021, the Company recorded a goodwill decrease of $0.8 million which related to the impact of foreign currency translation adjustments. The components of the Company’s identifiable intangible assets as of December 31, 2021 and September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ September 30, 2021 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,235 ​ $ 1,026 ​ $ 209 ​ $ 1,242 ​ $ 1,002 ​ $ 240 Completed technology ​ 75,554 ​ 34,176 ​ 41,378 ​ 75,527 ​ 32,383 ​ 43,144 Trademarks and trade names ​ 424 ​ 37 ​ 387 ​ 424 ​ 33 ​ 391 Non-competition agreements ​ ​ 681 ​ ​ 297 ​ ​ 384 ​ ​ 681 ​ ​ 249 ​ ​ 432 Customer relationships ​ 253,577 ​ 117,346 ​ 136,231 ​ 253,486 ​ 111,159 ​ 142,327 Other intangibles ​ ​ 244 ​ ​ 244 ​ ​ — ​ ​ 246 ​ ​ 246 ​ ​ — ​ ​ $ 331,715 ​ $ 153,126 ​ $ 178,589 ​ $ 331,606 ​ $ 145,072 ​ $ 186,534 ​ Amortization expense for intangible assets was $8.0 million and $8.9 million, for the three months ended December 31, 2021 and 2020, respectively. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2022, the subsequent four fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ ​ 2022 ​ $ 24,099 2023 ​ 30,845 2024 ​ 27,354 2025 ​ 22,574 2026 ​ 19,435 Thereafter ​ 54,282 ​ ​ $ 178,589 ​ ​ ​

Line of Credit

Line of Credit	3 Months Ended
	Dec. 31, 2021
Line of Credit
Line of Credit Facility [Line Items]
Line of Credit	7. Line of Credit The Company maintained a revolving line of credit under a credit agreement with Wells Fargo Bank, N.A. and JPMorgan Chase Bank, N.A. that provided for a revolving credit facility of up to $75.0 million, subject to borrowing base availability, as defined in the credit agreement. ​ There were no amounts outstanding under the line of credit as of December 31, 2021 and September 30, 2021. The Company records commitment fees and other costs directly associated with obtaining the line of credit facility as deferred financing costs which are amortized over the term of the related financing arrangement. Deferred financing costs were $0.1 million for the period ended December 31, 2021 and September 30, 2021, respectively. The line of credit contains certain customary representations and warranties, a financial covenant and affirmative and negative covenants as well as events of default. The Company was in compliance with the line of credit covenants as of December 31, 2021. ​ As of February 1, 2022, subsequent to the close of our first fiscal quarter of 2022, the Company terminated the revolving credit facility.

Debt

Debt	3 Months Ended
	Dec. 31, 2021
Secured Debt
Debt Instrument [Line Items]
Debt	8. Debt Term Loans On October 4, 2017, the Company entered into a $200.0 million term loan with the lenders pursuant to the terms of a credit agreement. The term loan was issued at $197.6 million, or 98.8% of its par value, resulting in a discount of $2.4 million, or 1.2%, which represented loan origination fees paid at the closing. The Company’s obligations under the term loan are also guaranteed by Azenta US, Inc. (fka Brooks Life Sciences, Inc. and BioStorage Technologies, Inc.) as the guarantor, subject to the terms and conditions of the credit agreement. The Company and the guarantor granted the lenders a perfected first priority security interest in substantially all of the assets of the Company and the guarantor to secure the repayment of the term loan. The loan principal amount under the credit agreement may be increased by an aggregate amount equal to $75.0 million plus any voluntary repayments of the term loan plus any additional amount such that the secured leverage ratio of the Company is less than 3.00 to 1.00. Subject to certain conditions stated in the credit agreement, the Company may redeem the term loan at any time at its option without a significant premium or penalty, except for a repricing transaction, as defined in the credit agreement. The Company is required to redeem the term loan at the principal amount then outstanding upon occurrence of certain events, including (i) net proceeds received from the sale or other disposition of the Company’s or the guarantor’s assets, subject to certain limitations, (ii) casualty and condemnation proceeds received by the Company or the guarantor, subject to certain exceptions, or (iii) net proceeds received by the Company or the guarantor from the issuance of debt or disqualified capital stock after October 4, 2017. Commencing on December 31, 2018, the Company was required to make principal payments equal to the excess cash flow amount, as defined in the credit agreement. Such prepayments are equal to 50% of the preceding year excess cash flow amount reduced by voluntary prepayments of the term loan, subject to certain limitations. The deferred financing costs are accreted over the term of the loan using the effective interest rate method and are included in “Interest expense” in the accompanying unaudited Consolidated Statements of Operations. At December 31, 2021, the outstanding principal balance of the term loan was $49.7 million, excluding unamortized deferred financing costs of $0.3 million. The credit agreement contains certain customary representations and warranties, covenants and events of default. If any of the events of default occur and are not waived or cured within applicable grace periods, any unpaid amounts under the credit agreement will bear an annual interest rate at 2.00% above the rate otherwise applicable under the terms and conditions of such agreement. The credit agreement does not contain financial maintenance covenants. As of December 31, 2021, the Company was in compliance with all covenants and conditions under the credit agreement. During the three months ended December 31, 2021, the weighted average stated interest rate paid on all outstanding debt was 2.7%. During the three months ended December 31, 2021, the Company incurred aggregate interest expense of $0.4 million in connection with the borrowings, including $0.1 million of deferred financing costs amortization. The following are the future minimum principal payment obligations under all of the Company’s outstanding debt as of December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ Amount 2022 ​ $ — 2023 ​ ​ — 2024 ​ ​ — 2025 ​ ​ 50,000 Total outstanding principal balance ​ ​ 50,000 Unamortized deferred financing costs ​ ​ (298) ​ ​ ​ 49,702 Current portion of long-term debt ​ ​ — Non-current portion of long-term debt ​ $ 49,702 ​ ​

Leases

Leases	3 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	9. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate in North America, Europe, and Asia. Non-real estate leases are primarily related to vehicles and office equipment. Lease expiration dates range between 2022 and 2041. The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ ​ $ 2,171 ​ $ 1,704 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ ​ 75 ​ ​ 311 ​ Interest on lease liabilities ​ ​ ​ ​ ​ 3 ​ ​ 16 ​ Total finance lease costs ​ ​ ​ ​ ​ 78 ​ ​ 327 ​ Variable lease costs ​ ​ ​ ​ ​ 518 ​ ​ 406 ​ Short-term lease costs ​ ​ ​ ​ ​ 354 ​ ​ 38 ​ Total lease costs ​ ​ ​ ​ $ 3,121 ​ $ 2,475 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ September 30, 2021 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ $ 47,971 ​ $ 49,650 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ $ 5,342 ​ $ 5,254 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ 43,802 ​ ​ 45,088 ​ Total operating lease liabilities ​ ​ ​ ​ $ 49,144 ​ $ 50,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ $ 2,252 ​ $ 2,252 ​ Accumulated amortization ​ ​ ​ ​ ​ (2,180) ​ ​ (2,105) ​ Property, plant and equipment, net ​ ​ ​ ​ $ 72 ​ $ 147 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ $ 171 ​ $ 360 ​ Other long-term liabilities ​ ​ ​ ​ ​ (10) ​ ​ (10) ​ Total finance lease liabilities ​ ​ ​ ​ $ 161 ​ $ 350 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ 11.18 ​ ​ 11.33 ​ Finance leases ​ ​ ​ ​ ​ 0.33 ​ ​ 0.53 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ 3.89 % ​ 3.90 % Finance leases ​ ​ ​ ​ ​ 4.86 % ​ 4.87 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ ​ $ 1,659 ​ $ 1,432 ​ Operating cash flows from finance leases ​ ​ ​ ​ ​ 3 ​ ​ 16 ​ Financing cash flows from finance leases ​ ​ ​ ​ ​ 190 ​ ​ 304 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ $ 186 ​ $ 3,532 ​ ​ ​ Future lease payments for operating and finance leases as of December 31, 2021 were as follows for the remainder of fiscal year 2022, the subsequent five fiscal years and thereafter (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases ​ 2022 ​ ​ ​ ​ $ 5,428 ​ $ 171 ​ 2023 ​ ​ ​ ​ ​ 6,479 ​ ​ - ​ 2024 ​ ​ ​ ​ ​ 5,769 ​ ​ - ​ 2025 ​ ​ ​ ​ ​ 5,578 ​ ​ - ​ 2026 ​ ​ ​ ​ ​ 5,499 ​ ​ - ​ 2027 ​ ​ ​ ​ ​ 5,298 ​ ​ - ​ Thereafter ​ ​ ​ ​ ​ 27,574 ​ ​ - ​ Total future lease payments ​ ​ ​ ​ ​ 61,625 ​ ​ 171 ​ Less imputed interest ​ ​ ​ ​ ​ (12,481) ​ ​ (10) ​ Total lease liability balance ​ ​ ​ ​ $ 49,144 ​ $ 161 ​ ​ ​ As of December 31, 2021, the Company has entered into leases that have not commenced with future lease payments of $4.5 million. These leases are not yet recorded in the accompanying unaudited Consolidated Balance Sheets. These leases will commence in 2022 .

Income Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company recorded an income tax benefit of $4.7 million during the three months ended December 31, 2021. The benefit for the three months ended December 31, 2021 was primarily driven by a $4.8 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The Company recorded an income tax benefit of $1.6 million during the three months ended December 31, 2020. The tax benefit for the three months ended December 31, 2020 was primarily driven by a $1.9 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. During December 2020, the United States enacted the Consolidated Appropriations Act 2021 which also contains numerous income tax provisions among other tax and non-tax provisions. During March 2021, the United States enacted the American Rescue Plan Act of 2021. The Company evaluated the legislation of these Acts in relation to income taxes and determined that the income tax Acts do not have a material impact on its income tax provision. The Company evaluates the realizability of its deferred tax assets by tax-paying component and assesses the need for a valuation allowance on a quarterly basis. The Company evaluates the profitability of each tax-paying component on a historic cumulative basis and a forward-looking basis while performing this analysis. The Company maintains a U.S. valuation allowance related to the realizability of certain state tax credits and state net operating loss carry-forwards, as well as a valuation allowance against net deferred tax assets on certain foreign tax-paying components as of December 31, 2021. On February 1, 2022, the Company completed the sale of its semiconductor automation business that resulted in a taxable gain in the U.S. During the second quarter of fiscal year 2022, the Company may record adjustments to its valuation allowance as it considers new evidence including updated forecasts of U.S. income and utilization of deferred tax assets that were previously expected to expire. The Company maintains liabilities for uncertain tax positions. These liabilities involve judgment and estimation and are monitored based on the best information available. The Company recognizes interest related to unrecognized tax benefits as a component of the income tax provision or benefit. The Company recognized de minimis interest expense related to its uncertain tax positions during the three ended December 31, 2021. The Company is subject to U.S. federal, state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company’s interpretation of applicable tax laws in the jurisdictions in which it files. In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the U.S. and international jurisdictions, with the earliest tax year being 2013. Based on the outcome of these examinations or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Company’s Consolidated Balance Sheets. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefits and accrued interest on those benefits will be reduced by an amount of $0.4 million in the next twelve months due to statute of limitations expirations. These unrecognized tax benefits would impact the effective tax rate if recognized.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Balance Sheet Information	11. Other Balance Sheet Information The following is a summary of accounts receivable at December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ September 30, ​ ​ 2021 2021 Accounts receivable ​ $ 130,415 ​ $ 124,195 ​ Less allowance for expected credit losses ​ (4,414) ​ (4,318) ​ Accounts receivable, net ​ $ 126,001 ​ $ 119,877 ​ ​ The following is a summary of inventories at December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ September 30, ​ ​ 2021 2021 Inventories ​ ​ ​ Raw materials and purchased parts ​ $ 34,379 ​ $ 27,644 ​ Work-in-process ​ 1,835 ​ 4,787 ​ Finished goods ​ 33,929 ​ 27,967 ​ Total inventories ​ $ 70,143 ​ $ 60,398 ​ ​ Reserves for excess and obsolete inventory were $4.6 million and $3.7 million, respectively, at December 31, 2021 and September 30, 2021. At December 31, 2021 and September 30, 2021, the Company had cumulative capitalized direct costs of $23.2 million and $22.7 million, respectively, associated with the development of software for its internal use. As of December 31, 2021, this balance included $6.3 million associated with software still in the development stage which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets. During the three months ended December 31, 2021, the Company capitalized direct costs of $0.6 million associated with the development of software for its internal use. The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company. The following is a summary of product warranty and retrofit activity on a gross basis for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended December 31, 2021 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,330 ​ $ 673 ​ $ (660) ​ $ 2,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended December 31, 2020 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ Accruals ​ Costs Incurred ​ 2020 $ 2,211 ​ $ 648 ​ $ (592) ​ $ 2,267 ​

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 31, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation The Company may issue to eligible employees options to purchase shares of the Company’s stock, restricted stock and other equity incentives which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan, and stock awards and deferred restricted stock units to its directors in accordance with its director compensation program. The stock-based compensation expense for restricted stock units for continuing operations was $2.6 million and $4.5 million, for the three months ended December 31, 2021 and 2020, respectively. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.3 million for both the three months ended December 31, 2021 and 2020. The information included within the remaining note is on a total company basis, and includes amounts related to our discontinued operations. The following table reflects stock-based compensation expense recorded during the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ 2021 2020 Restricted stock units ​ $ 7,197 ​ $ 6,144 ​ Employee stock purchase plan ​ 694 ​ 566 ​ Total stock-based compensation expense ​ $ 7,891 ​ $ 6,710 ​ ​ The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusted for the probability percentage of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Each quarter, the Company assesses the probability of achieving the performance goals. Current estimates may differ from actual results and future changes in estimates. The Company grants restricted stock units that vest over a required service period and/or achievement of certain operating performance goals. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units, including stock awards, granted during the three months ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Three months ended December 31, 2021 149,348 59,776 24 89,548 Three months ended December 31, 2020 281,693 ​ 122,921 42 158,730 ​ Time-Based Grants Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third one-third one-third Stock Grants The stock awards granted to the members of the Company’s Board of Directors include stock awards and deferred restricted stock units. Certain members of the Board of Directors have elected to defer receiving their annual stock awards and related quarterly dividends until they attain a certain age or cease to provide services as the Company’s Board members. Stock awards granted in fiscal years 2022 and 2021 were vested as of the respective grant dates. Performance-Based Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals. Performance-based awards granted in fiscal year 2022, 2021 and 2020 allow participants to earn 100% of the restricted stock units if the Company’s performance meets its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals will be measured over a three-year period for each year’s awards and at the end of the period to determine the number of units earned by recipients who continue to meet the service requirement. Around the third anniversary of each year’s awards’ grant date, the Company’s Board of Directors determines the number of units earned for participants who continue to meet the service requirements on the vest date. Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the three months ended December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2021 1,088,652 ​ $ 47.35 Granted 149,348 ​ ​ 114.42 Vested (530,833) ​ ​ 37.57 Forfeited (38,951) ​ ​ 59.94 Outstanding at December 31, 2021 668,216 ​ ​ 71.19 ​ The weighted average grant date fair value of restricted stock units granted during the three months ended December 31, 2021 and 2020 was $114.42 and $68.49, respectively. The fair value of restricted stock units vested during the three months ended December 31, 2021 and 2020 was $64.8 million and $25.9 million, respectively. During the three months ended December 31, 2021 and 2020, the Company remitted $24.9 million and $9.6 million, respectively, collected from employees to satisfy their tax obligations as a result of share issuances. As of December 31, 2021, the unrecognized compensation cost related to restricted stock units that are expected to vest is $27.8 million and will be recognized over an estimated weighted average service period of approximately 2.1 years. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual offering period, whichever is lower. There were no shares purchased by employees under the employee stock purchase plan during the three months ended December 31, 2021 and 2020.

Earnings per Share

Earnings per Share	3 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings per Share	13. Earnings per Share The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three months ended December 31, 2021 and 2020 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ December 31, ​ ​ 2021 2020 Income from continuing operations ​ $ 2,858 ​ $ 2,706 ​ Income from discontinued operations, net of tax ​ 40,462 ​ 23,322 ​ Net income ​ $ 43,320 ​ $ 26,028 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic earnings per share ​ 74,630 ​ 74,021 ​ Dilutive restricted stock units ​ 236 ​ 262 ​ Weighted average common shares outstanding used in computing diluted earnings per share ​ 74,866 ​ 74,283 ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income per share: ​ ​ ​ Income from continuing operations ​ $ 0.04 ​ $ 0.04 ​ Income from discontinued operations, net of tax ​ 0.54 ​ 0.32 ​ Basic net income per share ​ $ 0.58 ​ $ 0.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income per share: ​ ​ ​ Income from continuing operations ​ $ 0.04 ​ $ 0.04 ​ Income from discontinued operations, net of tax ​ 0.54 ​ 0.31 ​ Diluted net income per share ​ $ 0.58 ​ $ 0.35 ​ Dividend declared per share ​ $ 0.10 ​ $ 0.10 ​ ​ During the three months ended December 31, 2021 and 2020, restricted stock units of 59,513 and 124,641 respectively, were excluded from the computation of diluted earnings per share as their effect would be antidilutive based on the treasury stock method.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	14. Revenue from Contracts with Customers Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ ​ 2021 ​ 2020 ​ Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 49,877 ​ $ 45,508 ​ Sample Repository Solutions ​ ​ ​ 25,871 ​ ​ 20,533 ​ Genomic Services ​ ​ ​ 63,904 ​ ​ 52,101 ​ Total ​ ​ $ 139,652 ​ $ 118,142 ​ ​ ​ Contract Balances Accounts Receivable, Net. Contract Assets. ​ Contract Liabilities. ​ Remaining Performance Obligations. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 37,409 ​ $ 15,971 ​ $ 53,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost to Obtain and Fulfill a Contract The Company capitalizes sales commissions when incurred if they are (i) incremental costs of obtaining a contract, (ii) expected to be recovered and (iii) have an expected amortization period that is greater than one year. As part of the Company’s cumulative effect adjustment, incremental costs associated with obtaining a contract were capitalized and have been classified as deferred commissions within the Company’s Consolidated Balance Sheet. These amounts primarily relate to sales commissions within the Life Sciences segments and are being amortized over a 60-month period, which represents the average period of contract performance. The Company did not capitalize any sales commissions during the three months ended December 31, 2021 as the amount of sales commissions that qualified for capitalization during the reporting period was insignificant. Sales commissions incurred during the reporting period have been expensed as incurred. These costs are recorded within “Selling, general and administrative” expenses on the Company’s Consolidated Statement of Operations. The Company has concluded that none of its costs incurred in fulfillment of customer contracts meet the capitalization criteria. The Company will account for shipping and handling activities as fulfillment activities and recognize the associated expense when control of the product has transferred to the customer.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment and Geographic Information	15. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments . The Company previously operated in The Life Sciences Products segment provides automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and instruments, that help customers manage samples throughout their research discovery and development workflows. The segment’s product offerings include automated cold storage systems, cryogenic storage systems, consumables and instruments and the associated services business for these products. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, as well as sample-based laboratory services to advance scientific research and support drug development. The segment’s service offerings include sample storage, genomic sequencing, gene synthesis, laboratory processing services, laboratory analysis, biospecimen procurement services and other support services which are provided to a wide range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories and research institutes. Our Sample Repository Solutions business is a global leader in sample and material storage and management and provides a full suite of reliable cold and ultra-cold chain solutions. The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the acquisition accounting impact on inventory contracts acquired, restructuring related charges and other special charges, such as impairment losses, in as the primary performance metric when evaluating the business. The following is the summary of the financial information for the Company’s reportable segments for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ 2021 ​ 2020 Revenue: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ ​ ​ $ 49,877 ​ $ 45,508 Life Sciences Services ​ ​ ​ ​ 89,775 ​ 72,634 Total revenue ​ ​ ​ ​ $ 139,652 ​ $ 118,142 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ ​ ​ $ 4,388 ​ $ 4,183 Life Sciences Services ​ ​ ​ ​ 7,883 ​ 6,928 Reportable segment adjusted operating income ​ ​ ​ ​ ​ 12,271 ​ ​ 11,112 Amortization of completed technology ​ ​ ​ ​ ​ 1,773 ​ ​ 2,005 Amortization of other intangible assets ​ ​ ​ ​ ​ 6,272 ​ ​ 6,905 Restructuring charges ​ ​ ​ ​ ​ 173 ​ ​ (40) Other unallocated corporate expenses (income) ​ ​ ​ ​ ​ 4,378 ​ ​ 1,885 Total operating (loss) income ​ ​ ​ ​ ​ (325) ​ ​ 356 Interest income ​ ​ ​ ​ ​ 35 ​ ​ 76 Interest expense ​ ​ ​ ​ ​ (455) ​ ​ (557) Other income (expenses), net ​ ​ ​ ​ ​ (1,077) ​ ​ 1,281 (Loss) income before income taxes ​ ​ ​ ​ $ (1,822) ​ $ 1,156 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ Life Sciences Products ​ Life Sciences Services ​ Total December 31, 2021 ​ $ 285,958 ​ $ 797,603 ​ $ 1,083,561 September 30, 2021 ​ 278,769 ​ ​ 780,238 ​ 1,059,007 ​ ​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, September 30, ​ ​ 2021 ​ 2021 Segment assets $ 1,083,561 $ 1,059,007 Cash and cash equivalents, restricted cash, and marketable securities ​ 231,817 ​ 244,012 Deferred tax assets ​ 13,845 ​ 10,043 Other assets ​ ​ 15,019 ​ ​ 11,237 Assets held for sale ​ 510,695 ​ 495,213 Total assets ​ $ 1,854,937 ​ $ 1,819,512 ​ Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three months ended December 31, 2021 and 2020 (in thousands) are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ 2021 ​ 2020 Geographic Location: ​ ​ ​ ​ ​ ​ North America ​ ​ 90,087 ​ ​ 73,588 Europe ​ ​ 28,594 ​ ​ 25,836 Asia / Pacific/ Other ​ ​ 20,971 ​ ​ 18,718 Total ​ $ 139,652 ​ $ 118,142 ​

Significant Customers

Significant Customers	3 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Significant Customers	16. Significant Customers The Company had no individual customer that accounted for 10% or more of its consolidated revenue for each of the three months ended December 31, 2021 and 2020. There was no customer that accounted for more than 10% of the Company’s accounts receivable balance as of both December 31, 2021 and September 30, 2021.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies Tariff Matter In fiscal year 2021, as part of the Company’s continued integration of GENEWIZ, which was acquired in November 2018, the Company initiated a review during first quarter of fiscal year 2021, with the assistance of a third party consultant, of the transaction value that the Company has used to calculate tariffs on inter-company imports of samples shipped from its GENEWIZ business. As a result of the third-party review and in light of a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed and as a result recorded a liability of $6.1 million in the second quarter of fiscal year 2021. Of the total liability, $2.8 million is for the period prior to the acquisition of GENEWIZ and an additional $3.3 million was recorded within the second fiscal quarter of 2021 for the period since the Company acquired GENEWIZ in November 2018. The Company estimates any additional liability for tariffs owed each period and as of December 31, 2021 and September 30, 2021, the liability for tariffs owed was $7.6 million and $7.0 million, respectively. The Company intends to pay any tariffs determined to be owed. The Company does not expect to incur any significant penalties associated with such tariffs. Letters of Credit As of December 31, 2021, the Company had approximately $1.3 million of letters of credit outstanding related primarily to customer advances and other performance obligations. These arrangements guarantee the refund of advance payments received from the Company’s customers in the event that the product is not delivered, or warranty obligations are not fulfilled in accordance with the contract terms. These obligations could be called by the beneficiaries at any time before the expiration date of the particular letter of credit if the Company fails to meet certain contractual requirements. None of these obligations were called during the three months ended December 31, 2021, and the Company currently does not anticipate any of these obligations to be called in the near future. Purchase Commitments At December 31, 2021, the Company had non-cancellable commitments of $59.9 million, including primarily purchase orders for inventory of $44.0 million, information technology related commitments of $14.2 million, and China facility commitments of $1.7 million. Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. Please refer to Note 3 “Discontinued Operations – Disposition of Semiconductor Cryogenics Business” to the Company’s consolidated financial statements included in the 2021 Annual Report on Form 10-K for more information on these claims. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Divestiture On February 1, 2022, the Company completed the sale of its semiconductor automation business to THL for $3.0 billion in cash subject to net working capital and other customary adjustments. The Company expects net cash proceeds from the sale to be approximately $2.4 billion, after adjustments, taxes and other items. Extinguishment of Debt and Termination of Credit Facility On February 1, 2022, in connection with the completion of the sale of its semiconductor automation business, the Company used $50.0 million of the cash proceeds from the sale to extinguish the total remaining outstanding balance of its term loan. The Company also closed its revolving credit facility of which is had no borrowings.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company applies the equity method of accounting to investments that provide it with the ability to exercise significant influence over the entities in which it lacks controlling financial interest and is not a primary beneficiary. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission for the fiscal year ended September 30, 2021 (the “2021 Annual Report on Form 10-K”). The accompanying Consolidated Balance Sheet as of September 30, 2021 was derived from the audited annual consolidated financial statements as of the period then ended.
Use of Estimates	Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue recognized in accordance with the percentage of completion method, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and record changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, sales, expenses, reserves and allowances, manufacturing and employee-related amounts, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods.
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses), net” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $1.9 million and net foreign currency transaction and remeasurement gains were $0.8 million during the three months ended December 31, 2021 and 2020, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of all of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income” in the Company’s Consolidated Balance Sheets and presented as a component of comprehensive income in the Company’s Consolidated Statements of Comprehensive Income.
Derivative Financial Instruments	Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than U.S. dollars. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses), net” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ December 31, ​ ​ 2021 2020 Realized losses on derivatives not designated as hedging instruments ​ $ (70) ​ $ (1,162) ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities, including cash equivalents and available for sale securities, at fair value. FASB ASC 820, Fair Value Measurement and Disclosures Level 1 Inputs: Level 2 Inputs: Level 3 Inputs: As of December 31, 2021, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns	Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers.
Leases	Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in the first quarter of fiscal 2023. The Company is evaluating the effect of adopting this new accounting guidance. ​ In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01 , Reference Rate Reform (Topic 848): Scope . The amendments provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the amendments are only available until December 31, 2022, when the reference rate replacement activity is expected to be completed. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures. ​ Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . There is no accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU will not affect the Company's consolidated financial statements. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s disclosure to the consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU.
Other	Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2021 Annual Report on Form 10-K. ​

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Realized gains (losses) on derivatives not designated as hedging instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ December 31, ​ ​ 2021 2020 Realized losses on derivatives not designated as hedging instruments ​ $ (70) ​ $ (1,162) ​

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ 2021 ​ 2020 Revenue ​ ​ ​ ​ ​ Products ​ $ 188,240 ​ $ 118,154 Services ​ ​ 15,430 ​ ​ 13,207 Total revenue ​ ​ 203,670 ​ ​ 131,361 Cost of revenue ​ ​ ​ ​ ​ ​ Products ​ ​ 107,597 ​ ​ 68,777 Services ​ ​ 8,309 ​ ​ 6,791 Total cost of revenue ​ ​ 115,906 ​ ​ 75,568 Gross profit ​ ​ 87,764 ​ ​ 55,793 Operating expenses ​ ​ ​ ​ ​ ​ Research and development ​ ​ 13,740 ​ ​ 10,994 Selling, general and administrative ​ ​ 22,676 ​ ​ 14,099 Restructuring charges ​ ​ - ​ ​ 127 Total operating expenses ​ ​ 36,416 ​ ​ 25,220 Operating income ​ ​ 51,348 ​ ​ 30,573 Other income (loss), net ​ ​ (46) ​ ​ (1,239) Income before income taxes ​ ​ 51,302 ​ ​ 29,334 Income tax provision ​ ​ 10,840 ​ ​ 6,012 Net income from discontinued operations ​ $ 40,462 ​ $ 23,322 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ ​ 2021 ​ ​ 2020 Depreciation and amortization ​ $ - ​ $ 2,019 Capital expenditures ​ $ 2,283 ​ $ 1,827 Stock-based compensation ​ ​ 4,923 ​ ​ 1,875 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ September 30, 2021 Assets ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 45,000 ​ $ 45,000 Accounts receivable, net ​ ​ 133,578 ​ ​ 142,256 Inventories ​ ​ 132,010 ​ ​ 110,735 Other current assets ​ ​ 13,945 ​ ​ 13,394 Total current assets of discontinued operation ​ $ 324,533 ​ $ 311,385 ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, net ​ $ 34,457 ​ $ 32,058 Long-term deferred tax assets ​ ​ 2,518 ​ ​ 3,167 Goodwill ​ ​ 81,514 ​ ​ 81,477 Intangibles, net ​ ​ 44,576 ​ ​ 44,468 Other assets ​ ​ 23,097 ​ ​ 22,658 Total long-term assets of discontinued operation ​ $ 186,162 ​ $ 183,828 ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 65,285 ​ $ 68,074 Deferred revenue ​ ​ 8,160 ​ ​ 7,141 Accrued warranty and retrofit costs ​ ​ 5,912 ​ ​ 6,081 Accrued compensation and benefits ​ ​ 20,963 ​ ​ 18,144 Accrued Income Taxes ​ ​ 6,184 ​ ​ 11,702 Accrued expenses and other current liabilities ​ ​ 14,454 ​ ​ 18,014 Total current liabilities of discontinued operation ​ $ 120,958 ​ $ 129,156 ​ ​ ​ ​ ​ ​ ​ Long-term tax reserves ​ ​ 2,373 ​ ​ 2,356 Long-term deferred tax liabilities ​ ​ 6,716 ​ ​ 6,548 Long-term pension liabilities ​ ​ 5,547 ​ ​ 5,490 Long-term operating lease liabilities ​ ​ 15,837 ​ ​ 15,425 Other long-term liabilities ​ ​ 1,503 ​ ​ 2,625 Total long-term liabilities of discontinued operation ​ $ 31,976 ​ $ 32,444 ​

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Fair Value, Including Accrued Interest Receivable and Unrealized Holding Gains (Losses) on Short-term and Long-term Marketable Securities	The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value December 31, 2021: ​ ​ ​ ​ Bank certificates of deposits ​ $ 25 ​ $ — ​ $ — ​ $ 25 Corporate securities ​ ​ 3,703 ​ ​ — ​ ​ — ​ ​ 3,703 Municipal securities ​ 46 ​ ​ — ​ ​ — ​ 46 ​ ​ $ 3,774 ​ $ — ​ $ — ​ $ 3,774 September 30, 2021: ​ ​ ​ ​ ​ Bank certificates of deposits ​ $ 30 ​ $ — ​ $ — ​ $ 30 Corporate securities ​ ​ 3,624 ​ ​ — ​ ​ — ​ ​ 3,624 Other debt securities ​ 25 ​ ​ — ​ ​ — ​ 25 ​ ​ $ 3,679 ​ $ — ​ $ — ​ $ 3,679 ​
Fair Value of Marketable Securities by Contractual Maturity	The fair values of the marketable securities by contractual maturities at December 31, 2021 are presented below (in thousands): ​ ​ ​ ​ ​ Fair Value Due in one year or less ​ $ 46 Due after one year through five years ​ 51 Due after five years through ten years ​ ​ — Due after ten years ​ 3,677 Total marketable securities ​ $ 3,774

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Goodwill by Business Segment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2021 ​ 110,138 ​ 359,218 ​ 469,356 Currency translation adjustments ​ (737) ​ (34) ​ (771) Balance, at December 31, 2021 ​ $ 109,401 ​ $ 359,184 ​ $ 468,585 ​
Components of Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets as of December 31, 2021 and September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ September 30, 2021 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,235 ​ $ 1,026 ​ $ 209 ​ $ 1,242 ​ $ 1,002 ​ $ 240 Completed technology ​ 75,554 ​ 34,176 ​ 41,378 ​ 75,527 ​ 32,383 ​ 43,144 Trademarks and trade names ​ 424 ​ 37 ​ 387 ​ 424 ​ 33 ​ 391 Non-competition agreements ​ ​ 681 ​ ​ 297 ​ ​ 384 ​ ​ 681 ​ ​ 249 ​ ​ 432 Customer relationships ​ 253,577 ​ 117,346 ​ 136,231 ​ 253,486 ​ 111,159 ​ 142,327 Other intangibles ​ ​ 244 ​ ​ 244 ​ ​ — ​ ​ 246 ​ ​ 246 ​ ​ — ​ ​ $ 331,715 ​ $ 153,126 ​ $ 178,589 ​ $ 331,606 ​ $ 145,072 ​ $ 186,534
Schedule of Future Amortization Expense	​ ​ ​ ​ ​ 2022 ​ $ 24,099 2023 ​ 30,845 2024 ​ 27,354 2025 ​ 22,574 2026 ​ 19,435 Thereafter ​ 54,282 ​ ​ $ 178,589 ​

Debt (Tables)

Debt (Tables)	3 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Future Minimum Principal Payment Obligations	​ ​ ​ ​ ​ ​ Amount 2022 ​ $ — 2023 ​ ​ — 2024 ​ ​ — 2025 ​ ​ 50,000 Total outstanding principal balance ​ ​ 50,000 Unamortized deferred financing costs ​ ​ (298) ​ ​ ​ 49,702 Current portion of long-term debt ​ ​ — Non-current portion of long-term debt ​ $ 49,702 ​

Leases (Tables)

Leases (Tables)	3 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of leases	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ ​ $ 2,171 ​ $ 1,704 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ ​ 75 ​ ​ 311 ​ Interest on lease liabilities ​ ​ ​ ​ ​ 3 ​ ​ 16 ​ Total finance lease costs ​ ​ ​ ​ ​ 78 ​ ​ 327 ​ Variable lease costs ​ ​ ​ ​ ​ 518 ​ ​ 406 ​ Short-term lease costs ​ ​ ​ ​ ​ 354 ​ ​ 38 ​ Total lease costs ​ ​ ​ ​ $ 3,121 ​ $ 2,475 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ September 30, 2021 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ $ 47,971 ​ $ 49,650 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ $ 5,342 ​ $ 5,254 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ 43,802 ​ ​ 45,088 ​ Total operating lease liabilities ​ ​ ​ ​ $ 49,144 ​ $ 50,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ $ 2,252 ​ $ 2,252 ​ Accumulated amortization ​ ​ ​ ​ ​ (2,180) ​ ​ (2,105) ​ Property, plant and equipment, net ​ ​ ​ ​ $ 72 ​ $ 147 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ $ 171 ​ $ 360 ​ Other long-term liabilities ​ ​ ​ ​ ​ (10) ​ ​ (10) ​ Total finance lease liabilities ​ ​ ​ ​ $ 161 ​ $ 350 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ 11.18 ​ ​ 11.33 ​ Finance leases ​ ​ ​ ​ ​ 0.33 ​ ​ 0.53 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ 3.89 % ​ 3.90 % Finance leases ​ ​ ​ ​ ​ 4.86 % ​ 4.87 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ ​ $ 1,659 ​ $ 1,432 ​ Operating cash flows from finance leases ​ ​ ​ ​ ​ 3 ​ ​ 16 ​ Financing cash flows from finance leases ​ ​ ​ ​ ​ 190 ​ ​ 304 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ $ 186 ​ $ 3,532 ​
Schedule of future lease payments of operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases ​ 2022 ​ ​ ​ ​ $ 5,428 ​ $ 171 ​ 2023 ​ ​ ​ ​ ​ 6,479 ​ ​ - ​ 2024 ​ ​ ​ ​ ​ 5,769 ​ ​ - ​ 2025 ​ ​ ​ ​ ​ 5,578 ​ ​ - ​ 2026 ​ ​ ​ ​ ​ 5,499 ​ ​ - ​ 2027 ​ ​ ​ ​ ​ 5,298 ​ ​ - ​ Thereafter ​ ​ ​ ​ ​ 27,574 ​ ​ - ​ Total future lease payments ​ ​ ​ ​ ​ 61,625 ​ ​ 171 ​ Less imputed interest ​ ​ ​ ​ ​ (12,481) ​ ​ (10) ​ Total lease liability balance ​ ​ ​ ​ $ 49,144 ​ $ 161 ​ ​
Schedule of future lease payments of finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases ​ 2022 ​ ​ ​ ​ $ 5,428 ​ $ 171 ​ 2023 ​ ​ ​ ​ ​ 6,479 ​ ​ - ​ 2024 ​ ​ ​ ​ ​ 5,769 ​ ​ - ​ 2025 ​ ​ ​ ​ ​ 5,578 ​ ​ - ​ 2026 ​ ​ ​ ​ ​ 5,499 ​ ​ - ​ 2027 ​ ​ ​ ​ ​ 5,298 ​ ​ - ​ Thereafter ​ ​ ​ ​ ​ 27,574 ​ ​ - ​ Total future lease payments ​ ​ ​ ​ ​ 61,625 ​ ​ 171 ​ Less imputed interest ​ ​ ​ ​ ​ (12,481) ​ ​ (10) ​ Total lease liability balance ​ ​ ​ ​ $ 49,144 ​ $ 161 ​ ​ ​

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Accounts Receivable	The following is a summary of accounts receivable at December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ September 30, ​ ​ 2021 2021 Accounts receivable ​ $ 130,415 ​ $ 124,195 ​ Less allowance for expected credit losses ​ (4,414) ​ (4,318) ​ Accounts receivable, net ​ $ 126,001 ​ $ 119,877 ​
Summary of Inventories	The following is a summary of inventories at December 31, 2021 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ September 30, ​ ​ 2021 2021 Inventories ​ ​ ​ Raw materials and purchased parts ​ $ 34,379 ​ $ 27,644 ​ Work-in-process ​ 1,835 ​ 4,787 ​ Finished goods ​ 33,929 ​ 27,967 ​ Total inventories ​ $ 70,143 ​ $ 60,398 ​
Product Warranty and Retrofit Activity on Gross Basis	The following is a summary of product warranty and retrofit activity on a gross basis for the three months ended December 31, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended December 31, 2021 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,330 ​ $ 673 ​ $ (660) ​ $ 2,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended December 31, 2020 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ Accruals ​ Costs Incurred ​ 2020 $ 2,211 ​ $ 648 ​ $ (592) ​ $ 2,267

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ 2021 2020 Restricted stock units ​ $ 7,197 ​ $ 6,144 ​ Employee stock purchase plan ​ 694 ​ 566 ​ Total stock-based compensation expense ​ $ 7,891 ​ $ 6,710 ​ ​
Restricted Stock Unit Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Three months ended December 31, 2021 149,348 59,776 24 89,548 Three months ended December 31, 2020 281,693 ​ 122,921 42 158,730 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2021 1,088,652 ​ $ 47.35 Granted 149,348 ​ ​ 114.42 Vested (530,833) ​ ​ 37.57 Forfeited (38,951) ​ ​ 59.94 Outstanding at December 31, 2021 668,216 ​ ​ 71.19

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share	The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three months ended December 31, 2021 and 2020 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ December 31, ​ ​ 2021 2020 Income from continuing operations ​ $ 2,858 ​ $ 2,706 ​ Income from discontinued operations, net of tax ​ 40,462 ​ 23,322 ​ Net income ​ $ 43,320 ​ $ 26,028 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic earnings per share ​ 74,630 ​ 74,021 ​ Dilutive restricted stock units ​ 236 ​ 262 ​ Weighted average common shares outstanding used in computing diluted earnings per share ​ 74,866 ​ 74,283 ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income per share: ​ ​ ​ Income from continuing operations ​ $ 0.04 ​ $ 0.04 ​ Income from discontinued operations, net of tax ​ 0.54 ​ 0.32 ​ Basic net income per share ​ $ 0.58 ​ $ 0.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income per share: ​ ​ ​ Income from continuing operations ​ $ 0.04 ​ $ 0.04 ​ Income from discontinued operations, net of tax ​ 0.54 ​ 0.31 ​ Diluted net income per share ​ $ 0.58 ​ $ 0.35 ​ Dividend declared per share ​ $ 0.10 ​ $ 0.10 ​

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue by Reporting Unit	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ ​ 2021 ​ 2020 ​ Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 49,877 ​ $ 45,508 ​ Sample Repository Solutions ​ ​ ​ 25,871 ​ ​ 20,533 ​ Genomic Services ​ ​ ​ 63,904 ​ ​ 52,101 ​ Total ​ ​ $ 139,652 ​ $ 118,142 ​ ​
Remaining Performance Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 37,409 ​ $ 15,971 ​ $ 53,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Financial Information for Business Segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ ​ ​ ​ ​ 2021 ​ 2020 Revenue: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ ​ ​ $ 49,877 ​ $ 45,508 Life Sciences Services ​ ​ ​ ​ 89,775 ​ 72,634 Total revenue ​ ​ ​ ​ $ 139,652 ​ $ 118,142 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ ​ ​ $ 4,388 ​ $ 4,183 Life Sciences Services ​ ​ ​ ​ 7,883 ​ 6,928 Reportable segment adjusted operating income ​ ​ ​ ​ ​ 12,271 ​ ​ 11,112 Amortization of completed technology ​ ​ ​ ​ ​ 1,773 ​ ​ 2,005 Amortization of other intangible assets ​ ​ ​ ​ ​ 6,272 ​ ​ 6,905 Restructuring charges ​ ​ ​ ​ ​ 173 ​ ​ (40) Other unallocated corporate expenses (income) ​ ​ ​ ​ ​ 4,378 ​ ​ 1,885 Total operating (loss) income ​ ​ ​ ​ ​ (325) ​ ​ 356 Interest income ​ ​ ​ ​ ​ 35 ​ ​ 76 Interest expense ​ ​ ​ ​ ​ (455) ​ ​ (557) Other income (expenses), net ​ ​ ​ ​ ​ (1,077) ​ ​ 1,281 (Loss) income before income taxes ​ ​ ​ ​ $ (1,822) ​ $ 1,156 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ Life Sciences Products ​ Life Sciences Services ​ Total December 31, 2021 ​ $ 285,958 ​ $ 797,603 ​ $ 1,083,561 September 30, 2021 ​ 278,769 ​ ​ 780,238 ​ 1,059,007 ​
Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, September 30, ​ ​ 2021 ​ 2021 Segment assets $ 1,083,561 $ 1,059,007 Cash and cash equivalents, restricted cash, and marketable securities ​ 231,817 ​ 244,012 Deferred tax assets ​ 13,845 ​ 10,043 Other assets ​ ​ 15,019 ​ ​ 11,237 Assets held for sale ​ 510,695 ​ 495,213 Total assets ​ $ 1,854,937 ​ $ 1,819,512
Revenue from External Customers Attributed to Geographic Areas	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended December 31, ​ 2021 ​ 2020 Geographic Location: ​ ​ ​ ​ ​ ​ North America ​ ​ 90,087 ​ ​ 73,588 Europe ​ ​ 28,594 ​ ​ 25,836 Asia / Pacific/ Other ​ ​ 20,971 ​ ​ 18,718 Total ​ $ 139,652 ​ $ 118,142

Nature of Operation (Details)

Nature of Operation (Details) - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business - Subsequent Event $ in Billions	Feb. 01, 2022USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 3
Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds after adjustments and deducting taxes and other items	$ 2.4

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Foreign Currency Translation (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Foreign Currency Transaction Gain (Loss), before Tax [Abstract]
Foreign currency transaction and remeasurement losses	$ (1.9)	$ (0.8)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [Abstract]
Realized losses on derivatives not designated as hedging instruments	$ (70)	$ (1,162)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Fair Value Measurements (Details) - Fair Value, Measurements, Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Dec. 31, 2021USD ($)
Assets
Assets measured at fair value	$ 0
Liabilities
Liabilities measured at fair value	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details)	Dec. 31, 2021
Accounting Standards Update 2021-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2020-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2020-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2019-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2021-08
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2018-14
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021

Discontinued Operations - Gener

Discontinued Operations - General Information (Details) $ in Thousands	Feb. 01, 2022USD ($)lease	Dec. 31, 2020USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Adjustment to the gain on divestiture, net of tax		$ 948
Thomas H. Lee Partners, L.P. | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition service agreement, term, low end of range	3 months
Transition service agreement, term, high end of range	24 months
Sale leaseback transaction, lease agreements, number | lease	2
Sale leaseback transaction, lease term	24 months
Sale leaseback transaction, termination notice period	90 days
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 3,000,000
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Subsequent Event | Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds after adjustments and deducting taxes and other items	$ 2,400,000
Discontinued Operations, Disposed of by Sale | Semiconductor Cryogenics Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Adjustment to the gain on divestiture, net of tax		$ 1,300

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net income from discontinued operations	$ 40,462	$ 23,322
Discontinued Operations, Held-for-sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	203,670	131,361
Total cost of revenue	115,906	75,568
Gross profit	87,764	55,793
Research and development	13,740	10,994
Selling, general and administrative	22,676	14,099
Restructuring charges		127
Total operating expenses	36,416	25,220
Operating income	51,348	30,573
Other income (loss), net	(46)	(1,239)
Income before income taxes	51,302	29,334
Income tax provision	10,840	6,012
Net income from discontinued operations	40,462	23,322
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Products
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	188,240	118,154
Total cost of revenue	107,597	68,777
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Services
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	15,430	13,207
Total cost of revenue	$ 8,309	$ 6,791

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Capital Expenditures (Details) - Discontinued Operations, Held-for-sale - Semiconductor Automation Business - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Depreciation and amortization		$ 2,019
Capital expenditures	$ 2,283	1,827
Stock-based compensation	$ 4,923	$ 1,875

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash and cash equivalents	$ 45,000		$ 45,000
Total current assets of discontinued operation	324,533	$ 311,385
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Total long-term assets of discontinued operation	186,162	183,828
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Total current liabilities of discontinued operation	120,749	128,939
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Total long-term liabilities of discontinued operation	31,976	32,444
Discontinued Operations, Held-for-sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash and cash equivalents	45,000	45,000
Accounts receivable, net	133,578	142,256
Inventories	132,010	110,735
Other current assets	13,945	13,394
Total current assets of discontinued operation	324,533	311,385
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Property, plant and equipment, net	34,457	32,058
Long-term deferred tax assets	2,518	3,167
Goodwill	81,514	81,477
Intangibles, net	44,576	44,468
Other assets	23,097	22,658
Total long-term assets of discontinued operation	186,162	183,828
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Accounts payable	65,285	68,074
Deferred revenue	8,160	7,141
Accrued warranty and retrofit costs	5,912	6,081
Accrued compensation and benefits	20,963	18,144
Accrued Income Taxes	6,184	11,702
Accrued expenses and other current liabilities	14,454	18,014
Total current liabilities of discontinued operation	120,958	129,156
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Long-term tax reserves	2,373	2,356
Long-term deferred tax liabilities	6,716	6,548
Long-term pension liabilities	5,547	5,490
Long-term operating lease liabilities	15,837	15,425
Other long-term liabilities	1,503	2,625
Total long-term liabilities of discontinued operation	$ 31,976	$ 32,444

Discontinued Operations - Acqui

Discontinued Operations - Acquisitions (Details) - USD ($) $ in Thousands	Apr. 29, 2021	Dec. 31, 2021	Sep. 30, 2021
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill		$ 468,585	$ 469,356
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc.
Business Acquisition, Date of Acquisition [Abstract]
Business acquisition, effective date of acquisition	Apr. 29, 2021
Business Combination, Consideration Transferred [Abstract]
Total purchase price	$ 69,800
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	33,100
Deferred tax liabilities	$ 6,200
Weighted average useful life of intangible assets	11 years
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes	$ 0
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc. | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	38,700
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc. | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	$ 2,500

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 3,774	$ 3,679
Fair Value	3,774	3,679
Certificates of Deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	25	30
Fair Value	25	30
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,703	3,624
Fair Value	3,703	3,624
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	46
Fair Value	$ 46
Other debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		25
Fair Value		$ 25

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Due in one year or less (remainder of year)	$ 46
Due in one year	0
Due after one year through five years	51
Due after ten years	3,677
Fair Value	$ 3,774	$ 3,679

Marketable Securities - Unreali

Marketable Securities - Unrealized Loss Position (Details) - USD ($) $ in Millions	Dec. 31, 2021	Sep. 30, 2021
Debt Securities, Available-for-sale, Unrealized Loss Position [Abstract]
Fair value of marketable securities in unrealized loss position	$ 0	$ 0

Acquisitions - General Informat

Acquisitions - General Information (Details)	Apr. 02, 2021	Dec. 03, 2020
Abeyatech LLC
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Apr. 2, 2021
Trans-Hit Biomarkers
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition		Dec. 3, 2020

Acquisitions - Purchase Conside

Acquisitions - Purchase Consideration (Details) - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 03, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Net cash outflow			$ 15,061
Abeyatech LLC
Business Acquisition [Line Items]
Net cash outflow	$ 9,900
Acquisition-related contingent consideration	$ 9,400
Trans-Hit Biomarkers
Business Acquisition [Line Items]
Total purchase price		$ 15,100

Acquisitions - Amounts of Asset

Acquisitions - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021	Apr. 02, 2021	Dec. 03, 2020
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 468,585	$ 469,356
Abeyatech LLC
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill			$ 4,400
Intangible assets			11,900
Other assets and liabilities, net			$ 3,000
Trans-Hit Biomarkers
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill				$ 9,300
Intangible assets				7,800
Long-term deferred tax liabilities				$ (2,400)

Acquisitions - Intangible Asset

Acquisitions - Intangible Assets Acquired (Details)	Apr. 02, 2021	Dec. 03, 2020
Abeyatech LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	12 years
Trans-Hit Biomarkers
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		11 years

Acquisitions - Goodwill (Detail

Acquisitions - Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021	Apr. 02, 2021	Dec. 03, 2020
Business Combination, Goodwill [Abstract]
Goodwill	$ 468,585	$ 469,356
Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill	109,401	110,138
Life Sciences Services
Business Combination, Goodwill [Abstract]
Goodwill	$ 359,184	$ 359,218
Abeyatech LLC
Business Combination, Goodwill [Abstract]
Goodwill			$ 4,400
Abeyatech LLC | Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes			$ 4,400
Trans-Hit Biomarkers
Business Combination, Goodwill [Abstract]
Goodwill				$ 9,300
Trans-Hit Biomarkers | Life Sciences Services
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes				$ 0

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Roll Forward - Tabular Disclosure (Details) $ in Thousands	3 Months Ended
	Dec. 31, 2021USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 469,356
Currency translation adjustments	(800)
Goodwill, ending balance	468,585
Life Sciences Products
Goodwill [Roll Forward]
Goodwill, beginning balance	110,138
Currency translation adjustments	(737)
Goodwill, ending balance	109,401
Life Sciences Services
Goodwill [Roll Forward]
Goodwill, beginning balance	359,218
Currency translation adjustments	(34)
Goodwill, ending balance	359,184
Other
Goodwill [Roll Forward]
Goodwill, beginning balance	469,356
Currency translation adjustments	(771)
Goodwill, ending balance	$ 468,585

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Goodwill Roll Forward - Additional Information (Details) $ in Millions	3 Months Ended
	Dec. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Currency translation adjustments	$ (0.8)

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 331,715	$ 331,606
Accumulated Amortization	153,126	145,072
Net Book Value	178,589	186,534
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	1,235	1,242
Accumulated Amortization	1,026	1,002
Net Book Value	209	240
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	75,554	75,527
Accumulated Amortization	34,176	32,383
Net Book Value	41,378	43,144
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	424	424
Accumulated Amortization	37	33
Net Book Value	387	391
Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Cost	681	681
Accumulated Amortization	297	249
Net Book Value	384	432
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	253,577	253,486
Accumulated Amortization	117,346	111,159
Net Book Value	136,231	142,327
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Cost	244	246
Accumulated Amortization	$ 244	$ 246

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 8	$ 8.9

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022	$ 24,099
2023	30,845
2024	27,354
2025	22,574
2026	19,435
Thereafter	54,282
Net Book Value	$ 178,589	$ 186,534

Line of Credit (Details)

Line of Credit (Details) - USD ($) $ in Millions	Dec. 31, 2021	Sep. 30, 2021	Oct. 04, 2017
Line of Credit | Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity	$ 75
Outstanding line of credit	0	$ 0
Deferred finance costs	$ 0.1	$ 0.1
Secured Debt | Senior Secured Term Loan Facility
Line of Credit Facility [Line Items]
Face amount			$ 200

Debt - General Information (Det

Debt - General Information (Details) - Senior Secured Term Loan Facility - Secured Debt $ in Millions	Oct. 04, 2017USD ($)
Debt Instrument [Line Items]
Face amount	$ 200
Issue amount	$ 197.6
Percentage of par (as a percent)	98.80%
Discount	$ 2.4
Discount percentage (as a percent)	1.20%
Aggregate increase amount	$ 75
Maximum secured leverage ratio	3

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Oct. 04, 2017
Debt Instrument [Line Items]
Deferred financing costs	$ 298
Long-term debt	$ 49,702
Senior Secured Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Prepayments as a percentage of the preceding year excess cash flow (as a percent)	50.00%
Deferred financing costs	$ 300
Long-term debt	$ 49,700
Weighted average interest rate (as a percent)	2.70%
Interest expense	$ 400
Deferred financing costs amortization	$ 100
Interest rate above applicable rate (as a percent)		2.00%

Debt - Long-term Debt - Future

Debt - Long-term Debt - Future Minimum Principal Payment Obligations (Details) $ in Thousands	Dec. 31, 2021USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2025	$ 50,000
Total outstanding principal balance	50,000
Unamortized deferred financing costs	(298)
Long-term debt	$ 49,702

Debt - Long-term Debt - Current

Debt - Long-term Debt - Current and Non-current (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Long-term Debt, by Current and Noncurrent [Abstract]
Long-term debt	$ 49,702
Non-current portion of long-term debt	$ 49,702	$ 49,677

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Operating lease costs	$ 2,171	$ 1,704
Amortization of assets	75	311
Interest on lease liabilities	3	16
Total finance lease costs	78	327
Variable lease cost	518	406
Short-term lease costs	354	38
Total lease costs	$ 3,121	$ 2,475

Leases - Assets and Liabilities

Leases - Assets and Liabilities - Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Assets and Liabilities, Lessee [Abstract]
Operating lease right-of-use assets	$ 47,971	$ 49,650
Accrued expenses and other current liabilities	$ 5,342	$ 5,254
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term operating lease liabilities	$ 43,802	$ 45,088
Total lease liability balance	$ 49,144	$ 50,342

Leases - Assets and Liabiliti_2

Leases - Assets and Liabilities - Finance Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]
Property, plant and equipment, at cost	$ 2,252	$ 2,252
Accumulated amortization	(2,180)	(2,105)
Property, plant and equipment, net	$ 72	$ 147
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease Liability [Abstract]
Accrued expenses and other current liabilities	$ 171	$ 360
Finance Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Other long-term liabilities, net	$ (10)	$ (10)
Total finance lease liabilities	$ 161	$ 350

Leases - Additional Information

Leases - Additional Information (Details)	Dec. 31, 2021	Sep. 30, 2021
Leases [Abstract]
Weighted average remaining lease term, operating leases	11 years 2 months 4 days	11 years 3 months 29 days
Weighted average remaining lease term, finance leases	3 months 29 days	6 months 10 days
Weighted average discount rate, operating leases (as a percent)	3.89%	3.90%
Weighted average discount rate, finance leases (as a percent)	4.86%	4.87%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 1,659	$ 1,432
Operating cash flows from finance leases	3	16
Financing cash flows from finance leases	$ 190	$ 304

Leases - Assets Obtained in Exc

Leases - Assets Obtained in Exchange for Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee Disclosure [Abstract]
ROU assets obtained in exchange for lease liabilities, operating leases	$ 186	$ 3,532

Leases - Future Lease Payments

Leases - Future Lease Payments - Operating Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 5,428
2023	6,479
2024	5,769
2025	5,578
2026	5,499
2027	5,298
Thereafter	27,574
Total future lease payments	$ 61,625

Leases - Gross Difference - Ope

Leases - Gross Difference - Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 61,625
Less imputed interest	(12,481)
Total lease liability balance	$ 49,144	$ 50,342

Leases - Future Lease Payment_2

Leases - Future Lease Payments - Finance Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2022	$ 171
Total future lease payments	$ 171

Leases - Gross Difference - Fin

Leases - Gross Difference - Finance Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 171
Less imputed interest	(10)
Total finance lease liabilities	$ 161	$ 350

Leases - Future Lease Payment_3

Leases - Future Lease Payments Not Commenced (Details) $ in Millions	Dec. 31, 2021USD ($)
Leases [Abstract]
Leases that have not commenced with future lease payments	$ 4.5

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ (4,680)	$ (1,550)
Benefit related to stock compensation windfalls	$ 4,800	$ 1,900

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	Dec. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Anticipated unrecognized tax benefit reduction during next twelve months	$ 0.4

Other Balance Sheet Informati_3

Other Balance Sheet Information - Summary of Account Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable	$ 130,415	$ 124,195
Less allowance for expected credit losses	(4,414)	(4,318)
Accounts receivable, net	$ 126,001	$ 119,877

Other Balance Sheet Informati_4

Other Balance Sheet Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials and purchased parts	$ 34,379	$ 27,644
Work-in-process	1,835	4,787
Finished goods	33,929	27,967
Inventory, net	70,143	60,398
Reserves for excess and obsolete inventory	$ 4,600	$ 3,700

Other Balance Sheet Informati_5

Other Balance Sheet Information - Capitalized Direct Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2021	Sep. 30, 2021
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 23.2	$ 22.7
Capitalized computer software costs	0.6
Software Development
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 6.3

Other Balance Sheet Informati_6

Other Balance Sheet Information - Product Warranty and Retrofit Activity on Gross Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning Balance	$ 2,330	$ 2,211
Accruals for warranties	673	648
Costs incurred	(660)	(592)
Ending Balance	$ 2,342	$ 2,267

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 7,891	$ 6,710
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	7,197	6,144
Restricted Stock Units (RSUs) | Discontinued Operations, Held-for-sale
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	2,600	4,500
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	694	566
Employee Stock | Discontinued Operations, Held-for-sale
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 300	$ 300

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Granted - Tabular Disclosure (Details) - shares	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	149,348	281,693
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	59,776	122,921
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	24	42
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	89,548	158,730

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Restricted Stock Unit Grants (Details) - Restricted Stock, Time Based Shares	3 Months Ended
	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Restricted Stock Unit Grants (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Performance-based awards granted, percentage (as a percent)	100.00%	100.00%	100.00%
Performance-based awards granted, percentage, maximum threshold met (as a percent)	200.00%	200.00%	200.00%
Performance goal measurement period (in years)	3 years

Stock-Based Compensation - Re_2

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Shares
Outstanding at beginning of period (in shares)	1,088,652
Restricted stocks granted (in shares)	149,348	281,693
Vested (in shares)	(530,833)
Forfeited (in shares)	(38,951)
Outstanding at end of period (in shares)	668,216
Weighted Average Grant-Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 47.35
Granted (in dollars per share)	114.42	$ 68.49
Vested (in dollars per share)	37.57
Forfeited (in dollars per share)	59.94
Outstanding at end of period (in dollars per share)	$ 71.19

Stock-Based Compensation - Re_3

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)	$ 114.42	$ 68.49
Fair value of restricted stock awards vested	$ 64.8	$ 25.9
Proceeds from employees to satisfy tax obligation	$ 24.9	$ 9.6

Stock-Based Compensation - Re_4

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	3 Months Ended
	Dec. 31, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 27.8
Unrecognized compensation cost, estimated weighted average amortization period	2 years 1 month 6 days

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued under employee stock purchase plan (in shares)	0	0
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock (as a percent)	85.00%

Earnings per Share - Tabular Di

Earnings per Share - Tabular Disclosure (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net income
Income from continuing operations	$ 2,858	$ 2,706
Income from discontinued operations, net of tax	40,462	23,322
Net income	43,320	26,028
Net income attributable to Brooks Automation, Inc. - basic	43,320	26,028
Net income attributable to Brooks Automation, Inc. - diluted	$ 43,320	$ 26,028
Weighted average common shares outstanding used in computing diluted earnings per share
Weighted average common shares outstanding used in computing basic earnings per share (in shares)	74,630	74,021
Dilutive restricted stock units	236	262
Weighted average common shares outstanding used in computing diluted earnings per share (in shares)	74,866	74,283
Basic net income per share:
Income from continuing operations (in dollars per share)	$ 0.04	$ 0.04
Income from discontinued operations, net of tax (in dollars per share)	0.54	0.32
Basic net income per share (in dollars per share)	0.58	0.35
Diluted net income per share:
Income from continuing operations (in dollars per share)	0.04	0.04
Income from discontinued operations, net of tax (in dollars per share)	0.54	0.31
Diluted net income per share (in dollars per share)	0.58	0.35
Dividend declared per share (in dollars per share)	$ 0.10	$ 0.10

Earnings per Share - Anti-dilut

Earnings per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted earnings per share (in shares)	59,513	124,641

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregated By Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 139,652	$ 118,142
Life Sciences Products
Disaggregation of Revenue [Line Items]
Total revenue	$ 49,877	$ 45,508
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products
Sample Repository Solutions
Disaggregation of Revenue [Line Items]
Total revenue	$ 25,871	$ 20,533
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services
Genomic Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 63,904	$ 52,101
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Sep. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	$ 126,001	$ 119,877
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	18,800	15,300
Contract with Customer, Liability [Abstract]
Current contract liabilities	28,483	25,724
Contract liabilities	28,500	$ 25,700
Revenue recognized	$ 13,800

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Remaining Performance Obligations (Details) $ in Thousands	Dec. 31, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 53,380
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 37,409
Unsatisfied performance obligation, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 15,971
Unsatisfied performance obligation, period

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Costs to Obtain and Fulfill a Contract (Details)	Dec. 31, 2021
Capitalized Contract Cost [Abstract]
Sales commission amortization period	60 months

Segment and Geographic Inform_3

Segment and Geographic Information - General Information (Details) - segment	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2
Number of operating segments	2	2
Number of reportable segments, previously operated	3	3

Segment and Geographic Inform_4

Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Total revenue	$ 139,652	$ 118,142
Amortization of other intangible assets	8,000	8,900
Restructuring charges	173	(40)
Operating income (loss)	(325)	356
Interest income	35	76
Interest expense	(455)	(557)
Other income (expenses), net	(1,077)	1,281
(Loss) income before income taxes	(1,822)	1,156
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	1,773	2,005
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,272	6,905
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	49,877	45,508
Operating income (loss)	4,388	4,183
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	89,775	72,634
Operating income (loss)	7,883	6,928
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	139,652	118,142
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income (loss)	12,271	11,112
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense (income)	$ 4,378	$ 1,885

Segment and Geographic Inform_5

Segment and Geographic Information - Financial Information for Business Segments - Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total assets	$ 1,854,937	$ 1,819,512
Operating Segments
Segment Reporting Information [Line Items]
Total assets	1,083,561	1,059,007
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Total assets	285,958	278,769
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Total assets	$ 797,603	$ 780,238

Segment and Geographic Inform_6

Segment and Geographic Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Segment Reporting Information [Line Items]
Cash and cash equivalents, restricted cash, and marketable securities	$ 231,817	$ 244,012
Deferred tax asset	13,845	10,043
Other assets	15,019	11,237
Assets held for sale	510,695	495,213
Assets	1,854,937	1,819,512
Operating Segments
Segment Reporting Information [Line Items]
Assets	$ 1,083,561	$ 1,059,007

Segment and Geographic Inform_7

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 139,652	$ 118,142
Asia/Pacific/Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	20,971	18,718
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	90,087	73,588
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 28,594	$ 25,836

Commitments and Contingencies -

Commitments and Contingencies - Tariff Matter (Details) - USD ($) $ in Millions	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021
Tariffs
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual	$ 7.6	$ 7	$ 6.1
Tariffs, Period Prior to Acquisition
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual			2.8
Tariffs, Period after Acquisition
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual			$ 3.3

Commitments and Contingencies_2

Commitments and Contingencies - Letters of Credit (Details) $ in Millions	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Outstanding letters of credit	$ 1.3

Commitments and Contingencies_3

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Dec. 31, 2021USD ($)
Non-cancelable commitments
Other Commitments [Line Items]
Other commitment	$ 59.9
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other commitment	44
Non-cancelable IT-related commitments
Other Commitments [Line Items]
Other commitment	14.2
Non-cancelable China facility commitments
Other Commitments [Line Items]
Other commitment	$ 1.7

Subsequent Events - Divestiture

Subsequent Events - Divestiture (Details) - Subsequent Event - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business $ in Billions	Feb. 01, 2022USD ($)
Subsequent Event [Line Items]
Proceeds from divestiture	$ 3
Forecast
Subsequent Event [Line Items]
Cash proceeds after adjustments and deducting taxes and other items	$ 2.4

Subsequent Events - Extinguishm

Subsequent Events - Extinguishment of Debt and Termination of Credit Facility (Details) - USD ($) $ in Thousands	Feb. 01, 2022	Dec. 31, 2020
Subsequent Event [Line Items]
Cash proceeds to extinguish debt		$ 414
Subsequent Event | Senior Secured Term Loan Facility | Secured Debt
Subsequent Event [Line Items]
Cash proceeds to extinguish debt	$ 50,000